US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Exelixis, Inc. (EXEL) reported mixed results for the second quarter of 2025. Adjusted earnings of 75 cents per share beat the ...

Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $64 from $66 and keeps an Overweight rating on the shares ahead of ...

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

Bristol Myers Squibb is taking a strategic leap, offloading five immunology assets, including three in clinical stages, to a ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Research shows that dividends have played a significant role in total equity returns. According to a T. Rowe Price report, dividends have made up nearly one-third of US stock returns since 1926.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.